Orally bioavailable stilbenoids- compositions and therapeutic applications thereof

ABSTRACT

A novel, bioavailable and safe stilbenoid 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with an unexpected enhanced ability to prevent the accumulation of lipids accompanying the terminal differentiation of adipocytes, thereby inhibiting adipogenesis, and nutraceutical and cosmeceutical compositions comprising 3,5-dimethoxy-3,4′-dihydroxystilbene useful for anti-obesity and anti-cellulite therapy, are disclosed. Further the enhanced SIRT-1 activation ability of 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 and 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II are disclosed. The enhancement of SIRT-1 polypeptide activity of the said compounds is unexpectedly much higher than resveratrol or its natural analog pterostilbene. Sirtuin modulating compositions comprising an orally bioavailable SIRT-1 enhancing compounds (i) 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#I and (ii) 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II are also disclosed. An additional embodiment, also discloses the enhanced anti-Propionibacterium acnes activity of 3,5-dimethoxy-3,4′-dihydroxystilbenes represented by STR#I and compositions thereof.

This application is a continuation-in-part of U.S. patent applicationSer. No. No. 12/367,840 filed on Feb. 9, 2009.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention in general relates to natural fat modulators. Morespecifically, the present invention relates to novel, bioavailable andsafe stilbenoid 3,5-dimethoxy-3,4′-dihydroxystilbene possessing anunexpected enhanced ability to prevent the accumulation of lipidsaccompanying the terminal differentiation of adipocytes, therebyinhibiting adipogenesis. Useful compositions thereof for anti-obesityand anti-cellulite therapy are also described in the invention. Furtherthe present invention also discloses the enhanced SIRT-1 activationability of 3,5-dimethoxy-3,4′-dihydroxystilbene and2,3′,5′,6-tetrahydroxy-trans-stilbene. In addition, the presentinvention also discloses the enhanced anti-Propionibacterium acnesactivity of 3,5-dimethoxy-3,4′-dihydroxystilbenes and compositionsthereof.

2. Description of Prior Art

It is reported that dietary resveratrol(3,4′,5-trihydroxy-trans-stilbene) at 50 parts per million suppressedblood serum lipid peroxidase levels in rats and dose-dependentlysuppressed serum triglyceride levels, VLDL and LDL cholesterol levels[Miura, D.; Miura, Y.; Yagasaki, K. Hypolipidemic action of dietaryresveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearingrats. Life Sci. 2003, 73, 1393-400]. Naokatu Arakaki et al reported thattreatment of differentiated 3T3-L1 adipocytes with H⁺-ATP synthaseinhibitors (resveratrol; picceatannol) lead to a decrease in cytosoliclipid droplet accumulation.

Rimando et al.; document that pterostilbene(3,5-dimethoxy-4′-hydroxystilbene), a natural analog of resveratrol actsas a PPARα agonist and may be a more effective hypo-lipidemic agent thanresveratrol itself [J. Agric. Food Chem. 2005, 53, 3403-3407]. Thisdocumentation is further validated by Marudhamuthu Amarnath Sateesh andLeelavinothan Pari, who observed that pterostilbene significantly,lowered levels of triglycerides, phospholipids, free fatty acids andtotal cholesterol in the serum, liver and kidneys of diabetic rats[Journal of Applied Biomedicine, Volume 5 (2008), No 1).

Similarly, Soon-he-Kim et al. reported (Biochemical and biophysicalResearch Communications 372 (2008) 108-113) that Vitisin A, aresveratrol tetramer inhibited adipocyte differentiation mosteffectively among others including resveratrol, stilbesterol, AmpelopsinA, Vitisin B, 3,4′,5-Trimethoxy stilbene, and piceatannol. The studyshowed that 3,5-dihydroxy-4-methoxystilbene,3,5-dihydroxy-40-methoxystilbene, 3,5-dihydroxy-4-methylstilbeneacetate, resveratrol-3-O-B-D-glucoside, resveratrol-3-O-Glu hexaacetate,resveratrol triacetate, rhaponticin, rhaponticin hexaacetate,rhapontigenin, rhapontigenin triacetate, and e-viniferin had no effecton adipogenesis. This study is important prior art in that fatmodulation through adipogenesis inhibition is not a common feature amongall stilbenoids. Rather, there seems to be a phenomenon of selectivityoperating in stilbenoids to inhibit adipogenesis based on theirstructure and substituted functional groups. While some stilbenoidsbetter others in inhibiting adipogenesis, there are stilbenoids whichtotally fail to inhibit adipogenesis also.

Adding to the mounting body of evidence on the selective and variableeffect of stilbenes towards fat metabolism/modulation, the presentinventors disclose the adipogenesis inhibitory effect of3,5-dimethoxy-3,4′-dihydroxystilbene. The present inventors haveunexpectedly found that the adipogenesis inhibitory potential of thesaid molecule is 5000 times more effective than resveratrol, therebyfinding use in anti-obesity and anti-cellulite therapy. The inventorshave also found that the SIRT-1 modulatory effects of 3,5-dimethoxy-3,4′-dihydroxystilbene is far superior to resveratrol and pterostilbeneenhancing its value as a nutraceutical agent. The molecule also showsconsiderable promise as a nutraceutical agent in terms of safety profileand bioavailability. In addition, the said molecule also shows farsuperior anti-acne activity in terms of its anti-Propionibacterium acnesactivity when compared to resveratrol reported for the said activity.Also disclosed as a part of this invention is the enhanced SIRT-1modulating compound 2,3′,5′,6-tetrahydroxy-trans-stilbene.

The principle objectives of the present invention include:

-   -   (a) To disclose a novel, orally bioavailable and safe stilbenoid        with an unexpected enhanced ability to inhibit the accumulation        of lipids accompanying the terminal differentiation of        adipocytes, thereby inhibiting adipogenesis and compositions        thereof suitable as cosmeceuticals, nutraceuticals and        pharmaceuticals.    -   (b) To disclose a novel, orally bioavailable and safe enhanced        sirtuin modulating stilbenoids and compositions thereof suitable        as nutraceuticals and pharmaceuticals.    -   (c) To disclose novel stilbenoid inhibiting the growth of        Propionibacterium acnes in an enhanced manner and compositions        thereof suitable as cosmeceuticals.

The present invention fulfills the aforesaid principle objectives andprovides further related advantages.

SUMMARY OF THE INVENTION

The present invention discloses

-   -   1. A novel, safe and bioavailable stilbenoid        3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with        an unexpected enhanced ability to prevent the accumulation of        lipids accompanying the terminal differentiation of adipocytes,        thereby inhibiting adipogenesis and cosmeceutical,        pharmaceutical and nutraceutical compositions thereof useful for        anti-cellulite and anti-obesity therapy.

-   -   2. A novel, safe and bioavailable stilbenoid        3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with        an unexpected enhanced ability for SIRT-1 polypeptide modulation        (increased activity of SIRT-1 polypeptide) and cosmeceutical,        pharmaceutical and nutraceutical compositions thereof.

-   -   3. A novel, safe and bioavailable stilbenoid        3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with        an unexpected enhanced activity against Propionibacterium acnes        and cosmeceutical compositions thereof.

-   -   4. A novel, safe and bioavailable stilbenoid        2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II with        an unexpected enhanced ability for SIRT-1 polypeptide modulation        (increased activity of SIRT-1 polypeptide) and cosmeceutical,        pharmaceutical and nutraceutical compositions thereof.

-   -   5. Adipogenesis inhibitors represented by the general structure        STR#III, wherein R1=R₂ are aliphatic or aromatic side chains and        the resulting ether linkages thereof form primary, secondary or        tertiary ethers.

Other features and advantages of the present invention will becomeapparent from the following more detailed description, taken inconjunction with the accompanying drawings, which illustrate, by way ofexample, the principle of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 represents the microphotographs showing inhibition of adipocytedifferentiation and subsequent adipogenesis in 3T3-L1 mouse adipocytecells which have been treated with 3-hydroxypterostilbene. The untreatedcells show considerable lipid accumulation following adipocytedifferentiation.

FIGS. 1A and 1B represents a graphical representation of the comparativepercentage initial activity of the SIRT1 polypeptide activity withincreasing concentrations of Sirtinol, Resveratrol, Pterostilbene,Gnetol, 3-hydroxypterostilbene (3 hp) and oxyresveratrol;

FIGS. 2A and 2B show the graphical representations of 2,3′,5′,6-tetrahydroxy-trans-stilbene (gnetol) pharmacokinetics in the serumupon oral administration in animals.

FIGS. 3A, 3B and 3C shows the graphical representations of2,3′,5′,6-tetrahydroxy-trans-stilbene (gnetol) pharmacokinetics in theurine upon oral administration in animals.

FIG. 4 shows the graphical representations of3,5-dimethoxy-3,4′-dihydroxystilbene pharmacokinetics in the serum uponoral administration in animals.

FIGS. 5A and 5B shows the graphical representations of3,5-dimethoxy-3,4′-dihydroxystilbene pharmacokinetics in the urine uponoral administration in animals.

DETAILED DESCRIPTION OF THE MOST PREFERRED EMBODIMENT (FIGS. 1, 1A, 1B,2A, 2B, 3A, 3B, 3C, 4, 5A and 5B)

In the most preferred embodiment, the present invention discloses thenovel, safe, bioavailable stilbenoid3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with anunexpected enhanced ability to prevent the accumulation of lipidsaccompanying the terminal differentiation of adipocytes, therebyinhibiting adipogenesis and cosmeceutical, pharmaceutical andnutraceutical compositions thereof useful for anti-cellulite andanti-obesity therapy. 3,5-dimethoxy-3,4′-dihydroxystilbene is a naturalstilbenoid occurring from plant sources including but not limited toPterocarpus marsupium and Vitis vinifera. In a specific embodiment, thecosmeceutical compositions comprise from about 0.3% w/v to about 5% w/vof 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1. In yetanother most preferred embodiment, the present invention includesadipogenesis inhibitors represented by the general structure STR#III,wherein R₁=R₂ are aliphatic or aromatic side chains and the resultingether linkages thereof form primary, secondary or tertiary ethers. Inone embodiment, the invention also encompasses pharmaceutical,cosmeceutical and nutraceutical compositions comprising the adipogenesisinhibitors represented by STR#III. In a specific embodiment, thecosmeceutical compositions comprise from about 0.3% w/v to about 5% w/vof the adipogenesis inhibitors represented by STR#III.

In yet another preferred embodiment, the present invention discloses thenovel, safe and bioavailable stilbenoid3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with anunexpected enhanced ability for SIRT-1 polypeptide modulation (increasedactivity of SIRT-1 polypeptide) and pharmaceutical/nutraceuticalcompositions thereof.

In yet another preferred embodiment, the present invention discloses thenovel, safe and bioavailable stilbenoid2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#2 with anunexpected enhanced ability for SIRT-1 polypeptide modulation (increasedactivity of SIRT-1 polypeptide) and pharmaceutical/nutraceuticalcompositions thereof

As an additional embodiment, the present invention discloses the novel,safe and bioavailable stilbenoid 3,5-dimethoxy-3,4′-dihydroxystilbenerepresented by STR#1 with an unexpected enhanced activity againstPropionibacterium acnes and cosmeceutical compositions thereof. In aspecific embodiment, the cosmeceutical compositions comprise from about0.3% w/v to about 5% w/v of 3,5-dimethoxy-3,4′-dihydroxystilbenerepresented by STR#1.

The underlying paragraphs discuss in detail as specific examples (i)Adipogenesis inhibition by 3,5-dimethoxy-3,4′-dihydroxystilbene (EXAMPLE1; FIG. 1); (ii) the sirtuin modulating properties of3,5-dimethoxy-3,4′-dihydroxystilbene and2,3′,5′,6-tetrahydroxy-trans-stilbene (gnetol) in comparison (EXAMPLE 2,FIGS. 1A and 1B AND Table A) to resveratrol(3,4′,5-trihydroxy-trans-stilbene), its natural methoxylated derivative3,5-dimethoxy-4′-hydroxystilbene (pterostilbene) and Oxyresveratrol(trans-2,3′,4,5′-tetrahydroxystilbene); (iii) Antimicrobial Studies of3-hydroxy pterostilbene against Propionibacterium acnes (Example 3;TABLES B, C, D and E); (iv) Pharmacokinetics (EXAMPLE 4; FIGS. 2A, 2B,3A, 3B, 3C, 4, 5A and 5B); (v) Formulations (EXAMPLE 5); (vi)Miscellaneous in-house data (EXAMPLE 6; TABLE F); (vii) Safety data

EXAMPLE 1 FIG. I—Adipogenesis Inhibitory Activity

Principle:

A common assay to measure adipocyte differentiation in cell culture iswith the dye Oil Red-O, which is a lipid-soluble red dye. Since terminaldifferentiation of adipocytes is accompanied by the accumulation ofgreat amounts of lipids in large cytoplasmic vesicles, a strong, bright,staining of the cytoplasm with this dye is a reliable indicator ofadipocyte differentiation.

Methodology:

3T3-L1 mouse adipocyte cells are seeded at a density of 5000 cell/200 μlof adipocyte induction medium in a 96 well plate. After 48 hrs varyingconcentrations of the sample are added. After 72 hrs, the medium ischanged to adipocyte progression medium along with the sample. Themedium is similarly changed after another 48 hours. The plates arewashed gently after 48 hrs with 100 μl of PBS. 100 μl of 10% formalin isused to fix the cells for 30 min keeping at RT. The cells are thenwashed twice with 60% isopropanol gently. 100 μl of clear Oil red Ostain is added to the wells & kept for staining for 1 hr. The cells arethen washed with 70% Ethanol twice, once with PBS and air dried. Then100 μl of 4% triton×100 in isopropanol is added to all the wells coveredtightly & kept it in a shaker for 20 min at 25-300 C. The OD reading istaken at 492 nm in microplate reader.

Calculation:

The results are expressed as IC50 values using Graphpad prism software.The percentage of inhibition of adipogenesis is calculated as follows,

${\% \mspace{14mu} {Inhibition}} = {\frac{C - T}{C} \times 100}$

Where C-absorbance due to adipogenesis in untreated cells T-absorbancedue to adipogenesis in sample treated cells

Result:

-   (i) IC₅₀ of 3 Hydroxy Pterostilbene is 4.83 nM-   (ii) IC₅₀ of Resveratrol is 25 μM-   (iii) Reported IC₅₀ of pterostilbene is 23.9 μg/ml (Approximately 96    μm). [Modulation of lipid accumulation in 3T3-L1 cells by selected    polyphenols and Malus×domestics extracts in an in vitro adipogenesis    model-Connie M. Remsberg Jaime A. Yáñez^(1,2,) Karina    Vega-Villa^(1,2,3,) Jody K. Takemoto1,2, Preston K. Andrews³,    Neal M. Davies¹. 1 Pharmacology and Toxicology Graduate Program, 2    Department of Pharmaceutical Sciences, College of Pharmacy, 3    Department of Horticulture and Landscape Architecture, Washington    State University, Pullman, Wash. 99164-6414, USA]

Note: IC₅₀ is the concentration required for 50% inhibition ofadipogenesis. Lower IC50 indicates better efficacy.

3-Hydroxypterostilbene showed superior adipogenesis inhibitory potentialas compared to Resveratrol in maturing pre adipocytes. 3Hydroxypterostilbene is about 5000 times more superior to Resveratrolfor inhibition of Adipogenesis and hence a superior molecule for Antiobesity applications.

EXAMPLE 2 FIGS. IA and 1B

SIRT-1 activation/inhibition was measured using the SIRT 1 Directfluorescent Screening Assay kit (Catalog No. 10010401) and instructionsprovided therein of Cayman Chemical Company, 1180 East Ellsworth Road,Ann Arbor, Mich. 48108 USA.(http://www.caymanchem.com/pdfs/10010401.pdf)

TABLE A Percentage SIRT 1 modulation by stilbenoids Sirtinol 2-[(2-Hydroxynaphthalen- Sirtinol 2-[(2- Hydroxynaphthalen- Concentration 1-Concentration ylmethylene)amino]- 3-hydroxyPterostilbene (μg/ml)N-(1-phenyl-ethyl)•benzamide Resveratrol Pterostilbene Gnetol (3hp)Oxyresveratrol 1 64.44 137.78 2.22 104.44 224.44 77.78 10 −23326.67291.11 11.11 1846.67 668.89 24.44 50 −57517.78 1137.78 53.33 3686.671946.67 60.00 100 −60093.33 1471.11 113.33 4151.11 3146.67 202.22 250−56544.44 1902.22 231.11 4826.67 3771.11 297.78

Results (Table A) and Discussion

It may be known from Table A that both3,5-dimethoxy-3,4′-dihydroxystilbene (3-hydroxypterostilbene) and2,3′,5′,6-tetrahydroxy-trans-stilbene (gnetol) show enhanced percentageSIRT 1 modulation in comparison to resveratrol, Pterostilbene andOxyresveratrol at concentrations ranging from 10 μg/ml to 250 μg/ml.2,3′,5′,6-tetrahydroxy-trans-stilbene (gnetol) proves to be a betterSIRT 1 activator at concentrations ranging from 10 μg/ml to 250 μg/mlthan 3-hydroxypterostilbene. Added advantage is the oral bioavailabilityof these two compounds, namely 3,5-dimethoxy-3,4′-dihydroxystilbene(3-hydroxypterostilbene 3 hp)) and 2,3′,5′,6-tetrahydroxy-trans-stilbene(gnetol) as demonstrated by our data in FIG. 2A, FIG. 2B, FIG. 3A, FIG.3B, FIG. 3C, FIG. 4, FIG. 5A & FIG. 5B.

EXAMPLE 3 Tables B, C, D and E

Antimicrobial Studies of 3-Hydroxy Pterostilbene AgainstPropionibacterium acnes

Objective: To compare the effect of 3-Hydroxypsterostilbene andResveratrol on Propionibacterium acnes growth.

Propionibacterium acnes is a gram-positive, non-spore forming,anaerobic, pleomorphic rod found in clinical specimens. In human bodyP.acnes thrives on areas most exposed to air, such as the face and thenose. Its ability to live as an anaerobic in an air-exposed environmentcomes from the fact that P.acnes lives in the microhabitat sebaceousfollicles thus causing acne vulgaris.

Method: Disc diffusion method was done to study Minimum inhibitoryconcentration (MIC).

Materials

-   -   1. Propionibacterium acnes ATCC 11827    -   2. Physiological saline or Buffered peptone water (BPW).    -   3. Reinforced clostridium medium (RCM) Hi-media    -   4. Reinforced clostridium agar (RCA) Hi-media    -   5. Anaerobic chamber.    -   6. Gassing manifold Nitrogen, mixed gases.    -   7. Spectrophotometer (600 nm to 625 nm).    -   8. Sterile Petri plates (150 mm×90 mm).    -   9. Sterile micro pipettes and sterile micro tips.    -   10. Sterile disc 6 mm.    -   11. Samples tested: Resveratrol (Batch No.: C81173) and        3-Hydroxypsterostilbene (Batch No.: P80096)

Methods

Anaerobic Chamber

The chamber used in the study is of COY LABORATORY USA model 8301-230, 3ft polymer. The anaerobic chamber consists of a main chamber where inall the operations and incubation of the culture are carried out and atransfer chamber which is meant for taking the materials in and out ofthe equipment. The main chamber is provided with a heated fan box inorder to maintain the required temperature (37° C.) and to circulate theair in the chamber. A catalyst stakpak is fixed to this fan box whichconsists of palladium catalyst, which is meant to convert oxygen towater molecules by reacting with hydrogen molecules. The anaerobiccondition in the chamber for this is maintained by initialization withNitrogen gas and then by the Mixture gas of N₂+H₂+CO₂ in the proportion80:10:10. Two gas tank arrangements have been done where only N₂ isconnected to the transfer chamber.

Preparation of the Inoculum Propionibacterium acnes ATCC: 11827

To carry out the antimicrobial activity of the products against P.acnesthe organism was first cultured in the anaerobic conditions. Culture wasinoculated into pre-sterile reinforced Clostridium medium (RCM) andincubated at anaerobic condition for 24 hrs. 24 hr to 48 hrs culture atOptical Density @625 nm was determined 0.632 (1:2 dilution) 4.0Macfarland standards.

Procedure

30 ml of sterilized RCM was poured into the pre-sterile Petri platesinside the chamber and allowed to solidify. The culture was inoculated(0.2 ml/plate) and spread evenly. After 30 minutes, antibacterialsterile discs (6 mm) were dispensed. Samples in varying concentrations(0.4-5% w/v) were prepared using dimethylsulphoxide (DMSO) as thesolvent. 10 μl of the prepared sample and controls were dispensed ontothe discs. The plates were incubated inside the anaerobic chamber at 37°C. for 24 to 48 hours duration.

Results and Discussion (Table B)

TABLE B Sample: Sample: Resveratrol 3-Hydroxy Pterostilbene Batch:C81173 Zone of Batch: P80096 Zone of Concentration of inhibitionConcentration of inhibition sample % (w/v) (mm) sample % (w/v) (mm) 5.013.0 5.0 18.0 2.5 13.0 2.5 17.0 1.25 12.0 1.25 15.0 0.625 10.0 0.62513.0 0.31 No zone 0.31 10.0 0.156 No zone 0.156 No zone 0.078 No zone0.078 No zone DMSO No zone DMSO No zone

Clindac A® (Galderma India Pvt. Ltd., Mumbai) Anti-Acne Gel was used asReference Standard (Table C)

TABLE C Clindamycin phosphate USP (Anti acne cream) Concentration Zoneof inhibition SL. No. (% w/v) (mm) 01 1 8.0 02 0.1 No-zone 03 0.05No-zone Sterile water As such No-zone

Sample preparation: sterilized DM water

Discussion and Inference

From the studies 3-Hydroxy pterostilbene at 3.12 mg/ml (0.312% w/v)concentration produced a zone of inhibition of 10 mm while a higherconcentration of resveratrol 6.25 mg/ml (0.625% w/v) was required toproduce a similar effect. Reference standard Clindac A®, produced a 8 mmzone of inhibition at a concentration of 10 mg/ml (1.0% w/v).

Inhibitory Concentration (IC₅₀ and IC₁₀₀) Evaluation Studies

Method: Broth dilution method to evaluate the inhibitory concentration(IC).

Materials

-   -   1. Propionibacterium acnes ATCC: 11827    -   2. Physiological saline or Buffered peptone water (BPW).    -   3. Reinforced clostridium medium (RCM) Hi-media    -   4. Actinomyces broth (AC broth) Hi-media    -   5. Anaerobic chamber.    -   6. Gassing manifold Nitrogen, mixed gases.    -   7. Spectrophotometer (600 nm to 625 nm).    -   8. Sterile tubes    -   9. Micro Pipette    -   10. Sterile micro tips.    -   11. (DMSO) dimethylsulphoxide

The strain Propionibacterium acnes (ATCC 11827) was obtained from ATCC.The inhibitory concentration (IC) of the given sample was determined bybroth dilution method according to NCCLS guidelines. The IC₅₀ wasdefined as that concentration of compound that reduced bacterial growthby 50% as determined spectrophotometrically. IC₁₀₀ was defined as thelowest concentration of compound that inhibited bacterial growth by100%. Resveratrol and 3-Hydroxypsterostilbene are water insoluble.Therefore samples were dissolved in DMSO and than added to Actinomycesbroth to a final concentration of 0-500 mg/L. Twenty-four hour culturesof P.acnes were adjusted to 1×10⁸ cfu/ml using McFarland standards andinoculated to Actinomycetes broth containing a specific concentration ofcompound. Controls containing just DMSO were also included in the test.Cultures were incubated anaerobically at 37° C. and readspectrophotometrically at 600 nm both at 24 h and 48 h incubationperiods. IC₅₀ and IC₁₀₀ values were calculated from these observations.

Results (Table D):

OD @ Conc. 600 nm (IC) Inhibitory OD @ (IC) Inhibitory Sample (mg/L)Dilution 24 h concentration 600 nm 48 h concentration AC broth NA Assuch 0.131 NA 0.126 NA AC broth + NA 1:2 0.942 NA 0.820 NA culture3-Hydroxy 16.6 1:2 0.526 IC 45 0.443 IC 45 psterostilbene 41.6 1:2 0.352IC 62 0.338 IC 62 83.3 As such 0.047 IC 98 0.073 IC 98 166 As such — IC100 — IC 100 332 As such — IC 100 — IC 100 Resveratrol 16.6 1:2 1.027 Noinhibition 0.884 No inhibition 41.6 1:2 0.777 IC 17 0.593 IC 27 83.3 1:20.423 IC 55 0.573 IC 30 166 1:2 0.232 IC 75 0.268 IC 68 332 As such0.00  IC 100 0.11 IC 85 498 As such — IC 100 0.00 IC 100 NA: Notapplicable

Discussion and Inference (Table E)

TABLE E IC50 (mg/L) IC100 (mg/L) IC50 (mg/L) IC100 (mg/L) SAMPLE STRAIN24 h 24 h 48 h 48 h 3-Hydroxy P. acnes 33.5 83.3 35.8 83.0 pterostilbeneATCC 11827 P80096 Resveratrol P. acnes 83.0 332.0 120 498 C81173 ATCC11827 DMSO P. acnes No inhibition No inhibition No inhibition Noinhibition ATCC 11827

CONCLUSION

From the inhibitory concentration studies, both Resveratrol and3-HydroxypteroStilbene were capable of inhibiting P.acnes growth.3-Hydroxyptero-stilbene was found to be more effective against P.acnes.3-hydroxypterostilbene showed 100% inhibition of Propionibacterium acnesat concentrations of 83.3 mg/ml and 83 mg/ml following 24 hours and 48hours of incubation respectively. While resveratrol showed 100%inhibition of Propionibacterium acnes at concentrations of 332 mg/ml and498 mg/ml following 24 hours and 48 hours of incubation respectively.

EXAMPLE 4 Pharmacokinetic Studies

FIGS. 2A and 2B reveal that upon oral administration in rats of 100mg/kg body weight, it is evident that2,3′,5′,6-tetrahydroxy-trans-stilbene (gnetol) in its free form and as aglucoronide is orally bioavailable. The compound in its free andconjugated form is freely absorbed into systemic circulation with theglucoronide detected up to 72 hours. FIGS. 3A, 3B and 3C reveal that2,3′,5′,6-tetrahydroxy-trans-stilbene (gnetol) is excreted predominantlyas glucoronides in the urine, with glucoronides exhibiting a better rateof excretion.

Upon oral administration in rats of 100 mg/kg body weight, it is evidentthat 3,5-dimethoxy-3,4′-dihydroxystilbene (3-hydroxypterostilbene) inits free form and as a glucoronide is orally bioavailable. (FIG. 4). Thecompound in its free and conjugated form appears in systemic circulationwithin 15 minutes of administration.3,5-dimethoxy-3,4′-dihydroxystilbene (3-hydroxypterostilbene) isexcreted predominantly as glucoronides in the urine, with glucoronidesexhibiting a better rate of excretion (FIGS. 5A and 5B).

REFERENCES

-   1. John J. Docherty, Heather A. McEwen, Thomas J. Sweet, Erin Bailey    and Tristan D. Booth: “Resveratrol inhibition of propionibacterium    acnes”; Journal of antimicrobial chemotherapy (2007) 59, 1182-1184.    Advance Access publication 21 Apr. 2007;-   2. National committee for clinical laboratory standards-Methods for    Antimicrobial susceptibility testing of Anaerobic Bacteria-fifth    edition: Approved standards M11-A6.NCCLS, Wayne, Pa., USA, 2000

EXAMPLE 5 Formulations

Cosmeceutical formulations comprising3,5-dimethoxy-3,4′-dihydroxystilbene (3-hydroxypterostilbene)

Cosmeceutical Formulation I

Content % S. No. Formula w/w 1 3,5-dimethoxy-3,4′-dihydroxystilbene0.25-5   2 Tetra sodium EDTA 0.02 3 Imidurea 0.15 4 Sodium Methylparaben 0.20 5 Sodium Propyl paraben 0.02 6 Propylene glycol 2.00 7Carbopol U-10 0.20 8 Pemulene TR-1 0.15 9 GMS SE 1.00 10 Arlatone 21211.00 11 Arlacel 165 1.00 12 Elsoft 2.00 13 Elcast H 2.00 14 SodiumHydroxide (20% NaOH solution) 0.10 15 DC 3031 Fluid 0.50 16Demineralised water 84.66-89.41 100.00 

Cosmeceutical Formulation II

Content % S. No. Formula w/w 1 3,5-dimethoxy-3,4′-dihydroxystilbene0.25-5   2 Tetra sodium EDTA 0.02 3 Imidurea 0.15 4 Sodium Methylparaben 0.20 5 Sodium Propyl paraben 0.02 6 Propylene glycol 2.00 7Carbopol U-10 0.30 8 Pemulene TR-1 0.20 9 GMS SE 1.00 10 Arlatone 21211.00 11 Arlacel 165 1.00 12 Fluilan (Liquid lanolin) 2.00 13 CCTG 2.0014 Kokum butter 0.50 15 Sodium Hydroxide (20% NaOH solution) 0.10 16 DC3031 Fluid 0.50 17 Demineralised water 84.01-88.76 100.00 

Cosmeceutical Formulation III

Content % S. No. Formula w/w 1 3,5-dimethoxy-3,4′-dihydroxystilbene0.25-5   2 Carbopol U-10 0.20 3 Pemulene TR-1 0.15 4 Glycerine 2.00 5Arlatone 2121 1.00 6 GMS SE 2.00 7 Crill 4 2.00 8 Jojoba oil 2.00 9Kokum butter 0.50 10 Triethanolamine 1.00 11 Neolon PE 0.50 12Demineralised water 84.70-87.45 100.00 

Cosmeceutical Formulation IV (Lotion)

S. No. Formula Content % w/w 1 3,5-dimethoxy-3,4′- 0.25-5  dihydroxystilbene 2 Tetra sodium EDTA 0.05 3 Imidurea 0.50 4 Methylparaben 0.25 5 Propyl paraben 0.10 6 Propylene glycol 3.00 7 Glycerine3.00 8 GMS SE 1.00 9 CCTG 1.00 10 Iso Propyl Myristate 2.00 11 Lightliquid Prarffin 1.75 12 Soft Paraffin 1.00 13 Polawax 1.00 14 DC 3031Fluid 0.30 15 Salcare SC-91 0.60 16 Demineralised water 79.45-84.20100.00 

Nutraceutical/Pharmaceutical Formulations

3-hydroxypterostilbene Tablet

Label Claim: Each tablet contains: 3-hydroxypterostilbene=250 mg

Composition

1. 3-hydroxypterostilbene = 250 mg 2. Microcrystalline cellulose BP =190.0 mg 3. Maize Starch BP = 40.0 mg 4. Magnesium Stearate BP = 5.0 mg5. Sodium Starch Glycolate BP = 15.0 mg

3-hydroxypterostilbene Capsules

Label Claim: Each Capsule contains 3-hydroxypterostilbene=250 mg

Composition

1. 3-hydroxypterostilbene = 250 mg 2. Microcrystalline cellulose BP =38.0 mg 3. Maize Starch BP = 10.0 mg 4. Magnesium Stearate BP = 2.0 mg5. Hard Gelatin Capsules Size‘1’

Gnetol Capsules

Label Claim: Each Capsule contains: Gnetol=250 mg

Composition

1. Gnetol = 250 mg 2. Microcrystalline cellulose BP = 38.0 mg 3.Povidone BP = 10.0 mg 4. Magnesium Stearate BP = 2.0 mg 5. Hard GelatinCapsules Size‘1’

Gnetol Tablets

Label Claim: Each tablet contains Gnetol=250 mg

Composition

1. Gnetol = 250 mg 2. Microcrystalline cellulose BP = 190.0 mg 3.Povidone BP = 40.0 mg 4. Magnesium Stearate BP = 5.0 mg 5. Sodium StarchGlycolate BP = 15.0 mg

3-hydroxypterostilbene and Gnetol Tablets

Label Claim: Each tablet contains 3-hydroxypterostilbene=100 mg ANDGnetol=100 mg

Composition

1. 3-hydroxypterostilbene = 100 mg 2. Gnetol = 100 mg 3.Microcrystalline cellulose BP = 240.0 mg 4. Maize Starch BP = 40.0 mg 5.Magnesium Stearate BP = 5.0 mg 6. Sodium Starch Glycolate BP = 15.0 mg

3-hydroxypterostilbene and Epicatechin Capsules

Label Claim: Each tablet contains 3-hydroxypterostilbene=250 mg andEpicatechin=25.0 mg

Composition

1. 3-hydroxypterostilbene = 250 mg 2. Epicatechin = 25.0 mg 3.Microcrystalline cellulose BP = 13.0 mg 4. Maize Starch BP = 10.0 mg 5.Magnesium Stearate BP = 2.0 mg 6. Hard Gelatin Capsules Size‘1’

EXAMPLE 6 In-House Data for Miscellaneous Properties of3,5-dimethoxy-3,4′-dihydroxystilbene (Table F)

TABLE F Test Result ANTI OBESITY POTENTIAL Adipogenesis inhibitory assayIC₅₀ is 4.83 nM SKIN LIGHTENING POTENTIAL Melanin inhibitory assay inB16F1 mouse IC₅₀ is 0.7 μg/ml melanoma cell line ANTI TYROSINASEACTIVITY IC₅₀ is 2 μg/ml ANTIOXIDANT POTENTIAL Oxygen Radical AbsorbanceCapacity 13334 ± 323 μmol TE/100 g (ORAC) DPPH scavenging assay SC₅₀ is1.34 μg/ml ANTI INFLAMMATORY POTENTIAL Anti collagenase assay IC₅₀ is 90μg/ml Anti Elastase assay IC₅₀ is 82 μg/ml ANTI α-GLUCOSIDASE ACTIVITYIC₅₀ is 203.7 μg/ml

Safety Data:

3-hydroxypterostilbene is non mutagenic in the Bacterial reversemutation assay (AMES), both in the presence and absence of metabolicactivation, upto a workable concentration of 415 μg/ml.

Repeated dose 90 day Oral toxicity study for 3HPT in Sprague Dawleyrats: The study was conducted to evaluate the possible health hazardslikely to arise from repeated exposure to 3HPT over a relatively limitedperiod of time. The study was conducted in six groups consisting of 120rats with 60 males and 60 females. Group-I, I (R), II, III, IV and IV(R) served as Control, Control Recovery, Low dose (20 mg/kg Bwt), Middose (80 mg/kg Bwt), High dose (200 mg/kg Bwt) and High dose Recovery(200 mg/kg Bwt) groups respectively. The test item or vehicle wasadministered through oral route by gavage to animals daily for 90 days.The animals of Control group and Control recovery group wereadministered with Corn oil. The vehicle and test item administration toControl Recovery and High dose Recovery group animals respectively wasstopped after 90 days of administration and observed for another 28 daysto evaluate the effects during recovery period. The animals wereobserved for health status, clinical signs of toxicity and mortality,weekly detailed veterinary examination and subjected to neurologicalexamination. Body weights and food consumptions were recorded at weeklyintervals. On completion of 90 days for treatment groups or 118 days forrecovery groups respectively, the blood samples were collected from allthe animals and subjected to haematological and clinical chemistryevaluation. At termination the animals were humanely sacrificed andsubjected to necropsy examination. Histopathological examination wasconducted on the specified list of tissues from the control and the highdosage level group. Significant reduction in body weights and bodyweight gain observed in both the sexes at 200 mg/kg Bwt was considerednon adverse. Food consumption was comparable across the groups. Thehaematological and clinical chemistry data did not show any statisticalsignificance at all the doses tested. Necropsy and histopathologyexamination of tissues and organs did not reveal any pathologicalchanges. From the results of the study, the No-Observed-Adverse -Effect-Level (NOAEL) of 3-HYDROXYPTEROSTILBENE in Sprague Dawley rats,following oral route administration for 90 days was found to be 200mg/kg Bwt.

While the invention has been described with reference to a preferredembodiment, it is to be clearly understood by those skilled in the artthat the invention is not limited thereto. Rather, the scope of theinvention is to be interpreted only in conjunction with the appendedclaims.

1. A novel, orally bioavailable and safe stilbenoid3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1, saidstilbenoid useful with an unexpected enhanced ability to inhibit theaccumulation of lipids accompanying the terminal differentiation ofadipocytes and thereby inhibiting adipogenesis.


2. Compositions comprising the novel, orally bioavailable and safestilbenoid of claim
 1. 3. The compositions according to claim 2 whereinsaid compositions are nutraceutical compositions.
 4. The compositionsaccording to claim 2 wherein said compositions are pharmaceuticalcompositions.
 5. The compositions according to claim 2 wherein saidcompositions are cosmeceutical compositions.
 6. The compositionsaccording claim 5, wherein said compositions comprise from about 0.3%w/v to about 5% w/v of 3,5-dimethoxy-3,4′-dihydroxystilbene representedby STR#1.


7. An enhanced sirtuin modulating stilbenoid represented by STR#1.


8. An enhanced sirtuin modulating stilbenoid represented by STR#2


9. A stilbenoid inhibiting the growth of Propionibacterium acnes in anenhanced manner, said stilbenoid represented by STR#1


10. Cosmeceutical formulations comprising from about 0.3% w/v to about5% w/v of the stilbenoid of claim
 9. 11. Nutraceutical formulationscomprising the stilbenoid of claim
 7. 12. Nutraceutical formulationscomprising the stilbenoid of claim
 8. 13. Pharmaceutical formulationscomprising the stilbenoid of claim
 7. 14. Pharmaceutical formulationscomprising the stilbenoid of claim
 8. 15. Adipogenesis inhibitorsrepresented by the general structure STR#III, wherein R1=R₂ arealiphatic or aromatic side chains and the resulting ether linkagesthereof form primary, secondary or tertiary ethers.


16. Nutraceutical compositions comprising the inhibitors of claim 15.17. Pharmaceutical compositions comprising the inhibitors of claim 15.18. Cosmeceutical compositions comprising the inhibitors of claim 15.